MedTrace Logo

Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma

NCT00793845 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-09-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and toxicity of tandem HDCT/ASCR in children with high-risk neuroblastoma. In the present study, a single arm trial of tandem HDCT/ASCR will be carried out. In the present study, the investigators will investigate whether tandem HDCT/ASCR might improve the survival of patients with high-risk neuroblastoma with acceptable toxicity.

Conditions

Interventions

DRUG

Cyclophosphamide

First HDCT

DRUG

Etoposide

First HDCT

DRUG

Carboplatin

First HDCT

DRUG

Thiotepa

Second HDCT

DRUG

Melphalan

Second HDCT

RADIATION

Total body irradiation

Second HDCT

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Ki Woong Sung, MD · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2015-01-31
Completion
2018-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00793845 on ClinicalTrials.gov